Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis

Neurological Research

Volumn 27, Issue 7, 2005, Pages 768-772

  Nagano, Isao ^a   Shiote, Mito ^a   Murakami, Tetsuro ^a   Kamada, Hiroshi ^a   Hamakawa, Yoshiyuki ^a   Matsubara, Etsuro ^a   Yokoyama, Masataka ^a   Morita, Kiyoshi ^a   Shoji, Mikio ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Insulin like growth factor 1; Intrathecal administration; Norris scales; Vital capacity

Indexed keywords

ANTIALLERGIC AGENT; RECOMBINANT SOMATOMEDIN C;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; NORRIS SCALE; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SPINAL; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; MOTOR NEURON DISEASE; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 27244455282     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164105X39860     Document Type: Article

References (26)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819
2. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700
3. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
4. Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997; 41: 210-221
5. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature 1995; 373: 341-344
6. Gluckman P, Klempt N, Guan J, et al. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun 1992; 182: 593-599
7. Castro-Alamancos MA, Arevalo MA, Torres-Aleman I. Involvement of protein kinase C and nitric oxide in the modulation by insulin-like growth factor-I of glutamate-induced GABA release in the cerebellum. Neuroscience 1996; 70: 843-837
8. Kermer P, Klocker N, Labes M, et al. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 in vivo. J Neurosci 2000; 20: 2-8
9. Wang JM, Hayashi T, Zhang WR, et al. Reduction of ischemic brain injury by topical application of insulin-like growth factor-I after transient middle cerebral artery occlusion in rats. Brain Res 2000; 859: 381-386
10. Hantai D, Akaaboune M, Lagord C, et al. Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J Neurol Sci 1995; 129 (Supple.): 122-126
11. Vergani L, Di Giulio AM, Losa M, et al. Systemic administration of insulin-like growth factor decreases motor neuron cell death and promotes muscle reinnervation. J Neurosci Res 1998; 54: 840-847
12. Eustache I, Seyfritz N, Gueritaud JP. Effects of insulin-like growth factors on organotypic cocultures of embryonic rat brainstem slices and skeletal muscle fibers. Dev Brain Res 1994; 81: 284-292
13. Bilak MM, Kuncl RW. Delayed application of IGF-1 and GDNF can rescue already injured postnatal motor neurons. NeuroReport 2001; 12: 2531-2535
14. D'Costa AP, Prevette DM, Houenou LJ, et al. Mechanisms of insulin-like growth factor regulation of programmed cell death of developing avian motoneurons. J Neurobiol 1998; 36: 379-394
15. Kaspar BK, Lladó J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301: 839-842
16. Adem A, Ekblom J, Gillberg PG, et al. Insulin-like growth factor-I receptors in human spinal cord: changes in amyotrophic lateral sclerosis. J Neural Transm Gen Sect 1994; 97: 73-84
17. Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-1: potential use in the treatment of neu rodegenerative diseases. Trends Neurosci 1997; 20: 326-331
18. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-1 Study Group. Neurology 1997; 49: 1621-1630
19. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-1 Study Group. Neurology 1998; 51: 583-586
20. Brooks BR, Miller RG, Swash M, et al. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299
21. Norris FH, Calanchini PR, Fallat RH, et al. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721-728
22. Lacomblez L, Bouche P, Bensimon G, et al. A double-blind placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635-1637
23. Desnuelle C, Dib M, Garrel C, et al., the ALS riluzole-tocopherol Study Group. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotro Lateral Scler Other Motor Neuron Disord 2001; 2: 9-18
24. Nagano I, Ilieva H, Shiote M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J Neurol Sci 2005 (in press)
25. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with ALS. Amyotro Lateral Scler Other Motor Neuron Disord 2000; 3: 201-206
26. Corse AM, Bilak MM, Bilak SR, et al. Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiol Dis 1999; 5: 335-346